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Aim: Using matching-adjusted indirect comparison, we compared efficacy outcomes 
in patients with relapsing–remitting multiple sclerosis treated with delayed-release 
dimethyl fumarate (DMF) or glatiramer acetate (GA). Materials & methods: An 
indirect comparison of DMF (patient-level data) and GA (aggregate data) was 
conducted, with average baseline characteristics of DMF patients weighted to match 
those for GA patients. Direct comparison of DMF and GA was conducted in CONFIRM. 
Final results pooled the indirect and direct comparisons using meta-analysis. Results: 
After matching, baseline characteristics were balanced between DMF and GA 
patients. Compared with GA, efficacy was significantly in favor of DMF as measured 
by annualized relapse rate (rate ratio: 0.76; 95% CI: 0.57–1.00; p = 0.0474) and 12-
week confirmed disability progression (risk ratio: 0.59; 95% CI: 0.46–0.76; p < 0.0001). 
Conclusion: DMF demonstrated superior clinical efficacy versus GA.
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Published online: 28 March 2017
Keywords:  comparative effectiveness • delayed-release dimethyl fumarate • glatiramer 
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Multiple sclerosis (MS) is a chronic, inflam-
matory, demyelinating disease of the CNS [1] 
that affects over 400,000 individuals in the 
USA and 2.5 million worldwide [2]. Lesions 
caused by the inflammatory process result in 
symptoms including numbness, fatigue, limb 
weakness and gait instability, optic neuritis, 
bowel and bladder dysfunction, cognitive 
dysfunction, and depression [3,4]. When left 
untreated, relapses can become more frequent 
in the active phase of the disease and disabil-
ity increases over time; these two factors, 
more frequent relapses and greater disabil-
ity accumulation, are associated with poorer 
health-related quality of life [5].
Several disease-modifying therapies (DMTs) 
have been developed to effectively manage 
MS symptoms and delay disease progression 
with minimal adverse effects. Initially, these 
DMTs were administered parenterally, either 
via injection (e.g., glatiramer acetate [GA], 
IFN-β) or infusion (e.g., natalizumab, mito-
xantrone), but more recently, DMTs admin-
istered orally (e.g., delayed-release dimethyl 
fumarate [DMF], fingolimod, teriflunomide) 
have become available [4,6–7]. Although DMTs 
improve outcomes in patients with MS, there 
is still a lack of clarity with respect to the 
benefit–risk of disease compared with treat-
ment. Thus, sometimes therapies with safer 
profiles may be chosen over those that are 
perceived to have a greater risk.
DMF is indicated for the treatment of 
patients with relapsing forms of MS via oral 
administration and was approved for use in 
the USA, Canada and Australia in 2013 and 
for relapsing–remitting MS (RRMS) in the 
EU in 2014 [8–11]. As of 31 October 2016, 
over 230,000 patients have been treated 
with DMF worldwide, representing over 
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330,000 patient-years of exposure [12]. In Phase III tri-
als (DEFINE and CONFIRM), treatment with DMF 
240 mg two times a day (b.i.d.) resulted in significant 
reductions in annualized relapse rate (ARR), risk of 
relapse and mean number of new or newly enlarging 
T2 hyperintense lesions and nonenhancing T1 hypoin-
tense lesions compared with placebo (PBO) during the 
2-year study periods, and demonstrated favorable ben-
efit–risk profiles in patients with RRMS [13–15]. In an 
integrated analysis of DEFINE and CONFIRM, the 
risk of relapse at 2 years was reduced by 43% (p < 0.001) 
in patients treated with DMF 240 mg b.i.d. (hereafter 
referred to as DMF) compared with PBO [15].
GA is indicated for the treatment of patients with 
relapsing forms of MS via subcutaneous injections and 
was approved for use in the USA in 1996 [16]. In pilot and 
Phase III trials (US pivotal and European/Canadian 
pivotal [EUR/CAN]) [17–19], GA treatment resulted in 
significant relative reductions in clinical disease activ-
ity compared with PBO and demonstrated favorable 
benefit–risk profiles in patients with RRMS. Spe-
cifically, there was a significant relative reduction in 
ARR, mean number of new or newly enlarging T2 
hyperintense lesions and nonenhancing T1 hypoin-
tense lesions, and improvements in disability (as mea-
sured by Expanded Disability Status Scale [EDSS]) in 
patients treated with GA compared with PBO [17,18]. 
The mean relapse rate at 2 years was reduced by 29% 
(p < 0.01) for patients treated with GA compared with 
PBO [17]. The BEYOND trial found similar efficacy 
but different adverse event profiles for GA compared 
with IFN β-1b [20].
Although there is an increasing demand from pay-
ers and physicians for comparative effectiveness evalu-
ations to distinguish different treatment options, data 
from head-to-head trials among these agents are very 
limited. In the CONFIRM study, GA was included 
as a reference comparator only, thus the study was not 
designed or powered for head-to-head comparison of 
DMF versus GA. Head-to-head comparisons can also 
be difficult to perform methodologically due to the best 
practice approach of a double-blinded study design. 
However, data from multiple trials are available for 
establishing indirect comparison evidence. Although 
direct comparisons provide the best evidence, indi-
rect comparisons provide an alternative way to con-
duct effective comparisons [21]. Matching-adjusted 
indirect comparisons, unlike other indirect compari-
son methods, leverage all available data by compar-
ing individual patient data from studies of one agent 
with summary aggregate data from studies of another 
agent. The advantage of this method is that it adjusts 
for the observable aggregate cross-trial differences that 
might cause potential confounding to the comparison 
results [21]. However, like all other indirect comparison 
methods, matching-adjusted indirect comparisons are 
limited in that they cannot account for confounding 
resulting from unobservable cross-trial differences [21]. 
This method has been applied successfully in mul-
tiple diseases [22–25]. In the absence of randomized 
controlled trials involving direct treatment compari-
sons, indirect treatment comparisons can also be used 
by healthcare policy makers and payers to assess the 
decision to prescribe or cover a treatment [26].
GA and DMF are first-line treatments for relapsing 
forms of MS and are the most likely initial therapies 
for patients with RRMS, along with fingolimod, teri-
flunomide and IFN-βs according to recent Association 
of British Neurologist guidelines [27]. Patients with MS 
state a preference for oral therapies and indicate oral 
therapies may improve their quality of life [28]. Patient 
preference for oral therapies rather than injectable 
therapies increases as number of treatment switches, 
and therefore patient experience, grows [29]. Oral 
therapies may improve DMT adherence given that 
injection-related reasons, including injection site reac-
tions, injection fatigue and injection anxiety, account 
for a third of the reasons for nonadherence to inject-
able DMTs [30]. Compliance was shown to be greater 
at 6 months in patients taking oral therapies (fingo-
limod: 77%; teriflunomide: 77%; DMF: 62%) and 
receiving infusables (natalizumab: 69%) compared 
with patients receiving injectables (IFN β-1a or -1b or 
GA: 55%) [31]. Nonadherent patients reported worse 
quality of life [30].
The objective of this post hoc analysis was to com-
pare the efficacy of DMF with GA on measures of 
clinical disease activity at 2 years by combining the 
direct comparison results from CONFIRM and the 
indirect comparison results from multiple trials using a 
matching-adjusted indirect approach that adjusted for 
the observable cross-trial differences.
Materials & methods
Although a head-to-head direct comparison between 
DMF and GA was underpowered for CONFIRM, it 
allows for a direct comparison which was used here. 
For the indirect comparison, patients treated with 
DMF in the DEFINE and CONFIRM studies were 
weighted so that after weighting, the weighted mean 
matched to that of patients treated with GA in the 
US study, in the EUR/CAN study and in BEYOND 
(Figure 1 & Table 1). 
Several studies of GA were not included in this 
post hoc analysis because the end points were not 
defined in the same manner as the comparators and 
therefore the data could not be pooled. Specifically, 
ARR was either not reported (in Bornstein et al. [19]) or 
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Figure 1. Analysis method. 
EUR/CAN: European/Canadian; GA: Glatiramer acetate. 
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adjusted for the active-reference arm (in REGARD [32], 
CombiRx [33] and BECOME [34]). All ARR compari-
sons in this paper were analyzed using ARR adjusted 
for PBO. ARR adjusted for the active-reference arm 
could not be used because of the different treatment 
comparators: REGARD compared GA with IFN 
β-1a [32], BECOME compared GA with IFN β-1b [34] 
and CombiRx compared GA with IFN β-1a or treat-
ment with both GA and IFN β-1a [33]. These studies 
did not compare ARR for GA with PBO. Furthermore, 
12-week confirmed disability progression (CDP) was 
not reported in BECOME [34], REGARD [32], Born-
stein et al. [19] or CombiRx [33]. In REGARD [32] and 
CombiRx [33], 24-week CDP was reported but 12-week 
CDP was not. Therefore, the following studies were 
excluded from this analysis: REGARD [32], Com-
biRx [33], BECOME [34] and Bornstein et al. [19]. Given 
that the REGARD, CombiRx, BECOME and Born-
stein et al. publications did not publish PBO-adjusted 
ARR or 12-week CDP, we felt that it would not be 
appropriate or justifiable to include the studies in the 
primary analysis but we did conduct a sensitivity anal-
ysis in which these trials were included. For the sen-
sitivity analysis, first, the DMF arms from DEFINE 
and CONFIRM were pooled to calculate a pooled 
mean ARR for DMF; next, the GA arms from CON-
FIRM, US pivotal, EUR/CAN pivotal, BEYOND, 
REGARD, CombiRx and Bernstein et al. were pooled 
to calculate a pooled mean ARR; and finally a ratio 
of the two pooled mean ARRs for DMF and GA was 
assessed.
Patients & study design
DMF patient-level data were obtained from two mul-
ticenter, double-blind, randomized, Phase III stud-
ies: DEFINE, a 2-year, global, PBO-controlled trial 
(NCT00420212) [14] and CONFIRM, a 2-year, 
global, PBO-controlled, active-referenced (GA) trial 
Table 1. Studies included in analysis.
Study Arms Study duration (year) Primary end point ARR 12-week CDP
DEFINE DMF vs PBO 2 Time to relapse Yes Yes
CONFIRM DMF vs GA vs PBO 2 Time to relapse Yes Yes
GA US GA vs PBO 2 ARR Yes Yes
GA EUR/CAN GA vs PBO 1 Gd lesions Yes No
BEYOND GA vs IFN β-1b 2 Time to relapse No Yes
ARR data adjusted for PBO are not available for BEYOND. 
ARR: Annual relapse rate; CDP: Confirmed disability progression; DMF: Delayed-release dimethyl fumarate; GA: Glatiramer acetate; 
Gd: Gadolinium-enhancing; IFN: Interferon; PBO: Placebo. 
316 J. Comp. Eff. Res. (2017) 6(4) future science group
Research Article    Chan, Cutter, Fox, Xiao, Lewin & Edwards
(NCT00451451) [13]. GA aggregate data were obtained 
from three multicenter, randomized Phase III studies: GA 
US pivotal, a 2-year, US-based, double-blinded, PBO-
controlled trial (NCT00004814) [17]; GA EUR/CAN 
pivotal, a 9-month, European/Canadian-based, dou-
ble-blinded, PBO-controlled trial [18]; and BEYOND, 
a >2-year, global, open-label, active-comparator (IFN 
β-1b) trial (NCT00099502) [20]. Details of the study 
designs have been published previously [13–14,17–18,20].
Direct & indirect comparison statistical analysis
For the direct comparison of DMF b.i.d. versus GA 
in CONFIRM (analysis A), only data from the DMF 
b.i.d. and GA arms were used. The ARR rate ratios 
(RR) of DMF versus GA were estimated by a negative 
binomial model adjusted for baseline EDSS score, age, 
region and total number of relapses in the 12 months 
before study entry. A Cox proportional hazards model 
was used for analysis of time to disability progression 
adjusted for region, baseline EDSS score and age, where 
the hazard ratio of DMF versus GA was reported.
For the indirect comparison of DMF versus GA, only 
data from the DMF b.i.d. in DEFINE/CONFIRM 
were used and GA data were from other Phase III tri-
als (GA US, GA EUR/CAN and BEYOND; analy-
sis B). PBO data were used across all trials to obtain 
ARR RRs for active treatment against PBO. Data from 
the GA arm in CONFIRM was not used in the indi-
rect comparison (analysis B) because such data have 
already been used in the direct comparison (analysis 
A) and from a statistical perspective it was preferable 
not to use them twice. BEYOND employed an active 
comparator with no PBO arm (Table 1).
Matching-adjusted indirect comparison of 
DEFINE/CONFIRM and GA trials was conducted as 
described by Signorovitch et al. [25]. Individual patients 
in the pooled DMF trials were weighted such that their 
weighted average baseline characteristics (age, gender, 
race/ethnicity, time from onset of symptoms, number 
of relapses in previous year, EDSS [35] and use of any 
prior DMTs) matched those reported for patients in 
each GA trial. Of note, the EUR/CAN trial did not 
provide gender and race/ethnicity data, thus these two 
variables were not matched for the EUR/CAN trial. 
Prior treatment was one of the matching criteria, and 
the GA trials included only treatment-naive patients; 
thus, when patients from the DMF trials were matched 
to the GA study populations, only treatment-naive 
patients remained for comparison.
After matching, a weight was assigned to each 
individual patient in the DMF trials. With such 
weights [36], comparisons were made between DMF 
versus PBO across ARR and 12-week CDP by using 
the same models as those used in the direct compari-
son (analysis A) but leveraged by the weights. Of note, 
comparisons of GA versus PBO were obtained from 
GA publications. With the two treatments versus PBO 
comparison results, Bucher’s method was then used to 
compare DMF versus GA indirectly [36]. Final com-
parisons of DMF versus GA were obtained by pool-
ing the direct and indirect comparison results of DMF 
versus GA using random effects meta-analysis. CDP 
sustained for 24 weeks was not included as an outcome 
measure in the analysis because most of the GA tri-
als did not assess this end point. The definition of dis-
ability progression in DEFINE/CONFIRM was an 
≥1.5-point increase from a baseline EDSS score of 0, 
and an ≥1-point increase from a baseline EDSS score 
greater than 0. In the GA trials, the definition of dis-
ability progression was an ≥1-point increase regardless 
of baseline value, including patients who had a baseline 
score of 0.
Sensitivity analysis
A sensitivity analysis was conducted by excluding the 
BEYOND trial because the BEYOND trial had an 
active comparator and no PBO arm; all other studies 
included in this analysis were PBO controlled. Also, an 
analysis was conducted on the ARR results with and 
without the GA EUR/CAN trial because the study 
was only 9 months long.
Results 
Patients & trial comparisons
Before matching, the GA-treated patient population 
was slightly younger and included a greater percentage 
of white patients than the DMF-treated patient popu-
lation (Table 2). After matching, baseline characteris-
tics were balanced between DMF and GA patients for 
each of the matching-adjusted indirect comparisons 
(Table 3). The effective sample sizes are 1032, 1206 
and 364 after matching to the GA US, EUR/CAN, 
and BEYOND studies, respectively, because all the 
patients are included but treated with unequal weights. 
The effective sample size provides the correct sample 
size for converting the standard deviation of the re-
weighted outcome to a standard error. As previously 
noted, patients in the GA trials did not receive prior 
DMTs; thus, all patients included in this analysis after 
matching were DMT naive before entry into the DMF 
or GA studies.
Comparative effectiveness analysis of DMF 
versus GA
For the ARR comparison, DEFINE/CONFIRM, 
GA US and GA EUR/CAN had data available for 
ARR RR of active treatment versus PBO and were 
included in the analysis. Before matching, the 
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relative rate reduction for ARR at 2 years favored 
DEFINE/CONFIRM DMF-treated patients com-
pared with PBO-treated patients (relative rate reduc-
tion: 48%; p < 0.0001; Figure 2). Before matching 
the GA US and EUR/CAN studies, the relative rate 
reduction for ARR at 2 years was not significantly 
different between GA-treated patients compared 
with PBO-treated patients (relative rate reduction: 
30%; p = 0.1945 in the GA US study and 33%; 
p = 0.1504 in the GA EUR/CAN study, Figure 2). 
After matching to GA US and EUR/CAN stud-
ies, the relative rate reduction for ARR at 2 years 
favored DEFINE/CONFIRM DMF-treated patients 
compared with PBO-treated patients (relative rate 
reduction: 46%; p < 0.0001 and 55%; p < 0.0001, 
respectively). Compared with GA, efficacy was sig-
nificantly in favor of DMF as measured by the ARR 
with GA as the reference (relative rate reduction: 24%; 
p = 0.0474; Figure 2).
For efficacy measured by 12-week CDP, the rela-
tive risk reduction favored DEFINE/CONFIRM 
DMF-treated patients compared with PBO-treated 
patients before matching (relative risk reduction: 34%; 
p < 0.001) as well as after (relative risk reduction: 46%; 
p < 0.002; Figure 3). For efficacy measured by 12-week 
CDP, the relative risk reduction was not significantly 
Table 2. Baseline demographics of dimethyl fumarate† and glatiramer acetate patients before 
matching.
Characteristics Before matching
DMF† GA 
DEFINE CONFIRM US study EUR/CAN study BEYOND 
n 1234 1417 251 239 448
Age (years) 38.5 37.3 34.5 34.1 35.2
Female (%) 73.6 70.0 73.3 NR 68
White (%) 79 84 94 NR 91
Duration of MS (years) 8.3 7.7 7.0 8.1 5.1
Prior 1-year relapse 
rate
1.3 1.4 1.5‡ 1.3‡ 1.6
EDSS score 2.4 2.6 2.6 2.4 2.3
Any prior DMT (%)§ 41 29 0 0 0
†DMF: also known as gastro-resistant DMF. 
‡The prior 1-year relapse rate is approximated by half of the prior 2-year relapse rate. 
§The three GA trials do not allow pre-DMT-treated patients. 
DMF: Delayed-release dimethyl fumarate; DMT: Disease-modifying therapy; EDSS: Expanded Disability Status Scale; GA: Glatiramer acetate; 
MS: Multiple sclerosis; NR: Not reported. 
Table 3. Baseline demographics of dimethyl fumarate† patients after matching.
Characteristics DEFINE/CONFIRM DMF†
US matched EUR/CAN matched BEYOND matched
n‡ 1032 1206 364
Age (years) 34.5 34.1 35.2
Female (%) 73.3 NR 68
White (%) 94 NR 91
Duration of MS (years) 7.0 8.1 5.1
Prior 1-year relapse rate 1.5§ 1.3§ 1.6
EDSS score 2.6 2.4 2.3
Any prior DMT (%)§ 0 0 0
†DMF: also known as gastro-resistant DMF. 
‡n is the effective sample size that is computed as the square of the summed weights divided by the sum of the squared weights. 
§The prior 1-year relapse rate is approximated by half of the prior 2-year relapse rate. 
DMF: Delayed-release dimethyl fumarate; DMT: Disease-modifying therapy; EDSS: Expanded Disability Status Scale; GA: Glatiramer acetate; 
EUR/CAN: European/Canadian; MS: multiple sclerosis; NR: Not reported.
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Figure 2. Annualized relapse rate at 2 years†. 
†Rate ratio <1 indicates an improved outcome for DMF relative to GA, DMF relative to PBO or GA relative to PBO. 
DMF: also known as gastro-resistant DMF. 
Data not shown for the DEFINE/CONFIM versus BEYOND comparison because ARR adjusted for PBO was not 
available for BEYOND. The standard error of the rate ratio of GA versus PBO used for p-value calculation was 
approximated by:
Standard error of DMF vs PBO × Square root (sample size of GA trial) Square root (sample size of DMF trial). Closed 
symbols indicate risk ratio before matching, open symbols indicate risk ratio after matching, and shaded lines 
represent risk ratios from the pooled data. 
DMF: Delayed-release dimethyl fumarate; EUR/CAN: European/Canadian; GA: Glatiramer acetate; PBO: Placebo. 
Percent
relative
reduction
(%)
48 p < 0.001
p = 0.195
p = 0.150
p < 0.001
p < 0.001
p = 0.195
p = 0.150
p = 0.086
p = 0.027
p = 0.162
p = 0.047
30
33
46
55
30
33
22
23
22
24
Comparisons with PBO
Before matching
DMF vs GA
DEFINE/CONFIRM DMF vs PBO
DEFINE/CONFIRM DMF vs PBO
(US matched)
DEFINE/CONFIRM DMF vs PBO
(EUR/CAN matched)
US: GA vs PBO
EUR/CAN: GA vs PBO
US: GA vs PBO
EUR/CAN: GA vs PBO
After matching
CONFIRM: DMF vs GA
Before matching
Pooled: DMF vs GA
CONFIRM: DMF vs GA
After matching
Pooled: DMF vs GA
1.51.00.50.0
Rate ratio (95% CI)
Favors active
treatment
Favors DMF
0.78
0.77
0.78
0.76
Favors GA
Favors PBO
0.52
0.70
0.54
0.45
0.67
0.70
0.67
future science group
Research Article    Chan, Cutter, Fox, Xiao, Lewin & Edwards
different between GA-treated patients and PBO-treated 
patients in the GA US study before matching (relative 
risk reduction: 12%; p = 0.5734; Figure 3). Compared 
with GA, efficacy was significantly in favor of DMF 
as measured by 12-week CDP (relative risk reduction: 
41%; p < 0.0001) with GA as the reference (Figure 3).
Sensitivity analysis
In BEYOND, there was an active comparator and 
no PBO arm, and therefore a sensitivity analysis 
was done in which arm-to-arm indirect comparison 
result of DEFINE/CONFIRM versus BEYOND was 
excluded. In this sensitivity analysis, the risk ratio was 
0.69 (95% CI: 0.48–0.98; p = 0.041), consistent with 
those obtained in the primary analysis. The effect of 
the shorter study period for GA EUR/CAN on ARR 
was assessed using a sensitivity analysis. The trend of 
effec sizes is quite similar with or without the trial.
Discussion
Because data from head-to-head trials are limited, indi-
rect comparisons remain important, albeit imperfect, 
tools to address the comparative effectiveness of drugs. 
In order to further assess the relative effect of DMF 
versus GA, we performed a matching-adjusted indirect 
comparison of DMF with GA. Using this method, DMF 
demonstrated significantly favorable clinical efficacy 
compared with GA on ARR and also on 12-week CDP.
www.futuremedicine.com 319
Figure 3. 12-week confirmed disability progression†. 
†Risk ratio <1 indicates an improved outcome for DMF relative to GA, DMF relative to PBO or GA relative to PBO. 
DMF: also known as gastro-resistant DMF. 
Confirmed disability progression in GA US and BEYOND was defined as an ≥1-point increase in EDSS score 
sustained for 12 weeks. Data not shown for the GA EUR/CAN versus PBO comparison because CDP data were not 
available for GA EUR/CAN. p-value of the risk ratio for DMF versus PBO and GA versus PBO was based on the chi-
square test. Closed symbols indicate risk ratio before matching, open symbols indicate risk ratio after matching 
and shaded lines represent risk ratios from the pooled data. 
DMF: Delayed-release dimathyl fumarate; EDSS: Expanded Disability Status Scale; GA: Glatiramer acetate; 
PBO: Placebo.
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Other studies have compared DMTs for MS using 
different methods and obtained comparable results. 
A systematic review and data synthesis of DMF and 
other DMTs using mixed treatment comparisons 
found DMF significantly reduced ARR compared 
with GA (RR: 0.795 [95% CI: 0.668–0.947]) [37]. 
In an adjusted indirect comparison of DMF, teriflu-
nomide and laquinimod, using Bucher’s adjusted indi-
rect comparison method, it was found that relapse risk 
was lower with DMF compared with laquinimod or 
teriflunomide [38]. Roskell et al. performed an indirect 
comparison of ARR using mixed treatment compari-
son framework for fingolimod versus GA, IFN β-1b 
and IFN β-1a [39]. Fingolimod significantly reduced 
relapse frequency compared with injectable first-line 
DMTs. Zagmutt et al. performed a meta-analysis com-
paring adverse events for DMF, GA and teriflunomide, 
and showed that patients treated with GA may have 
better quality of life compared with DMF or teriflu-
nomide [40]. A recent indirect comparison of DMF 
versus fingolimod, using the same matching-adjusted 
comparison method, found DMF and fingolimod had 
similar effects on ARR, 12-week CDP, no evidence of 
disease activity and the Multiple Sclerosis Functional 
Composite, while DMF demonstrated greater benefit 
on the EuroQoL 5-Dimensions questionnaire utility 
score and visual analog scale compared with fingoli-
mod [41].A recent efficacy comparison using registry 
data found similar results. This comparative analysis 
of efficacy between DMF, fingolimod, GA, terifluno-
320 J. Comp. Eff. Res. (2017) 6(4) future science group
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mide and IFN compared data from the MSBase regis-
try using binomial propensity score matching followed 
by a generalized estimating Poisson model offset to 
estimate treatment exposure for ARRs [42]. The ARR 
was slightly higher in the DMF group compared with 
the matched fingolimod group (0.22 vs 0.19), while 
ARR was lower in the DMF group relative to either 
GA (0.24 vs 0.26), teriflunomide (0.17 vs 0.27) or IFN 
(0.23 vs 0.26) [42]. The methods used in the indirect 
comparison presented here are different to those used 
in the comparisons described above, yet similar results 
were found. Although it is possible that using alternate 
methods to conduct this comparison would lead to dif-
ferent results due to different assumptions made in the 
model, we felt the matching-adjusted indirect compar-
ison described by Signorovitch [25] and used here is the 
most appropriate, based on the available data.
Health economics studies have also used similar 
methods. Economic models using acquisition and 
healthcare cost data from Canada, France and the USA 
have shown that DMF is cost-effective compared with 
GA and fingolimod [43–46] Dorman et al. found the 
budget impact of adding DMF as a treatment would 
be partially offset by the reduced costs of relapses [47].
Smaller studies or small subsets of patients within 
studies allow direct comparisons of DMF and GA [13]. 
In CONFIRM, GA was included as reference arm. For 
both DMF and GA compared with PBO, a reduced 
rate of relapse, reduced mean number of new T1 
hypointense lesions, greater percentage of patients free 
from new or newly enlarging T2 hyperintense lesions 
and decreased odds of more gadolinium-enhancing 
lesions at 2 years were observed [13]. However, the 
study was not significantly powered to compare the 
DMF and GA arms [13]. A post hoc analysis of this 
subset of patients in CONFIRM found inflammatory 
disease activity over 2 years was significantly reduced 
in patients treated with DMF compared with patients 
treated with GA [48].
The time period of the studies included in this 
comparison is an important factor given changes in 
MS diagnosis, MS patient care, including timing of 
DMT treatment initiation, and known reductions in 
ARR that occurred over the first decade of the DMT 
era. Because the early pivotal trials had higher relapse 
rates, RRs were used instead of absolute rate for the 
ARR analysis. By using ARR RR, we found that the 
comparison results of DMF compared with GA are 
similar across different GA studies conducted in dif-
ferent years. That is, the RR of DMF compared with 
GA in CONFIRM (RR: 0.78 for both before and 
after matching), which was conducted in 2012, is 
quite similar to the RR of DMF compared with GA 
in the US pivotal study, which was conducted in 1990 
(RR: 0.73 before matching and 0.76 after matching) 
and EUR/CAN in approximately 2000 (RR: 0.77 
before matching and 0.67 after matching). The typical 
time delay between DMT treatment initiation relative 
to MS diagnosis had changed since some of the trials 
used in this analysis occurred. These potential tim-
ing differences to a certain point were reflected in the 
differences of patient demographics and MS disease 
characteristics and served as a rationale for the match-
ing adjustment performed in this analysis. The more 
recent studies (CONFIRM, DEFINE and BEYOND) 
have shown similar results that corroborate the results 
of the indirect comparison involving the two old GA 
trials and as a result, relieve the author’s concern of bias 
due to timing difference.
Although providing a valuable indirect compari-
son, the present analysis is not without limitation. 
This analysis relied on indirect comparison evidence, 
which involves all the caveats and limitations of an 
observational study, including confounding, selection 
and definitions of end points, and data availability [49]. 
Inclusion criteria were similar across trials however, 
differences are worth noting. Age varied between tri-
als, with younger patients in the GA trials. Specifi-
cally, patients were aged 18–45 years in the GA US 
trial, 18–50 years in the GA EUR/CAN trial, and 
18–55 years in DEFINE/CONFIRM and BEYOND. 
Also, the trials used different versions of the McDon-
ald diagnostic criteria [50]. The definition of disability 
progression was inconsistent across trials and there 
may have been differences in how missing EDSS scores 
were handled and what was done if a relapse occurred 
together with EDSS progression, which may have led 
to differences or bias across trials. Also, patients in GA 
trials were naive to prior DMTs. Matching can account 
for the difference of age and proportions of DMT-
naive patients; therefore, those factors were matched in 
the matching-adjusted indirect comparison. It was not 
possible to match the others, so residual confounders 
and bias due to the differences discussed above may 
have impacted the results [25]. In addition, the 2-year 
duration may not be sufficient to detect significance 
with CDP and also may not be long enough to assess 
the durability of the ARR treatment effect. The differ-
ences in defining CDP between trials may also limit 
the conclusions. The potential effects of unobserved or 
unknown differences are of course unknown. Finally, 
some trials were excluded because the end points were 
not defined in the same manner as the comparators 
and therefore the data could not be pooled. A sensitiv-
ity analysis was performed using a simple comparison 
as described in the ‘Materials & methods’ section. The 
results showed that the ARR relative rate reduction of 
DMF versus GA was 34% for adjusted ARR and 46% 
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for unadjusted ARR. Although there are many cave-
ats to this approach, these results are consistent with 
the more statistically rigorous matching-adjusted indi-
rect comparison (24%) presented in this manuscript 
and suggest that the exclusion of the studies dampens 
rather than amplifies the percent relative reduction 
calculated for DMF compared with GA.
Conclusion
DMF demonstrated significantly favorable clinical 
efficacy for both ARR and 12-week CDP versus GA in 
this matching-adjusted indirect comparison.
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Executive summary
•	 Matching-adjusted indirect comparisons can be useful when head-to-head comparisons are not available.
•	 This was a matching-adjusted indirect comparison between delayed-release dimethyl fumarate (DMF) and 
glatiramer acetate (GA), two first-line treatments for relapsing forms of multiple sclerosis (MS).
•	 Patients in the GA trials were DMT-naive; therefore, only DMT-naive patients from the DMF trials were 
included. Efficacy, as measured by annualized relapse rate, was significantly in favor of DMF, with GA as the 
reference (relative rate reduction: 24%; p = 0.0474).
•	 For 12-week confirmed disability progression, the relative risk reduction was 41% (p < 0.0001) in favor of DMF, 
with GA as the reference.
•	 A sensitivity analysis assessing the effect of a shorter study period showed similar results.
•	 Overall, DMF demonstrated significantly favorable clinical efficacy for both annualized relapse rate and 
12-week confirmed disability progression versus GA in this matching-adjusted indirect comparison.
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